User account access restricted unexpectedly

For the first time since her Stage IV ovarian cancer diagnosis in 2016, a patient has paused treatment after more than three years in a clinical trial. She describes the break as a “drug holiday.” Her oncologist agrees the decision makes sense. The experience feels like walking a high wire without a net.

The weight of a treatment that works

The decision wasn’t simple. The trial had kept her alive, shrinking lymph nodes where cancer cells lingered and producing what doctors called a “complete, lasting response.” Side effects, however, had grown unbearable: chronic diarrhea, fluid retention, and acid reflux so severe she relied on carbohydrates alone. Her weight increased. Cholesterol levels rose. She neared pre-diabetes.

She remained in the trial. “A cancer patient doesn’t abandon a treatment that works,” she told herself. “She persists, no matter the cost.”

In June, symptoms intensified. For two weeks, she couldn’t leave home. Her feet swelled too much for shoes. Her wedding rings wouldn’t fit. Severe diarrhea forced her husband to clean floors at midnight while she scrubbed the bathroom. She gained 15 pounds of water weight in days. Everything she ate passed through her system unchanged.

Tests returned normal results. Tumor markers, however, rose. She assumed the cancer had returned. Her oncologist ordered a CT scan immediately, expecting progression. Instead, the images showed no change—an outcome neither could explain. The symptoms gradually subsided. She lost the water weight, then another 14 pounds. Swelling receded, leaving her skin peeling from her feet and ankles.

The moment the scale tipped

The trial’s sponsor had already stopped producing the medication. She was the last participant remaining. Supplies would last until October, but by May, she thought about stopping. Side effects had stolen small pleasures: the crunch of an apple, the heat of spicy salsa, the texture of salad. “I just want to eat an apple again,” she told her doctor.

He didn’t object. A co-founder of nine Phase 1 clinical trial clinics globally, he called the break “reasonable.” Relief left her weak. The calculation was clear: being too ill to enjoy time with family defeated the purpose of survival.

Clinical trials often emphasize convenience—pills instead of infusions, fewer hospital visits. For some, the cost proves harsh. Targeted therapies can damage the gastrointestinal tract, forcing patients to balance survival against quality of life. The breaking point varies. For her, it came when treatment became harder than the disease itself.

Other cancer patients face the same struggle. Standard chemotherapy causes fatigue, nausea, and hair loss. Even newer options demand a price. The issue isn’t just whether drugs work, but whether they allow a meaningful life.

Three months of freedom—and uncertainty

She isn’t opting for hospice. She hasn’t given up on treatment. She’s taking three months without drug diaries, lab work, EKGs, or MUGA scans. No immune-boosting injections. No weekly clinic visits. Just the ability to eat blueberries, bell peppers, and vegetable stir-fries without fear. To wear shoes. To leave the house.

The risk remains. There’s no promise the next trial will succeed. “It’s like Russian roulette,” she writes. Her current oncologist is retiring, adding another layer of unpredictability. In three months, a new scan will guide the next steps. Until then, she’s adopting the unknown.

She plans to spend the break with family, writing her next novel, and reconnecting with her church community. “I’ll savor every moment,” she says. When the time comes, she’ll face the next challenge—whatever it brings.

For now, she’s eating apples.